The results validating the safety and first evidence of efficacy of Valedia® will be presented during a poster
Download the free guide
Boost your gains
June 11 from 12: 00 to 13: 00 (Hall B)
La Rochelle, on June 9, 2017 (7: 30 am CEST) – VALBIOTIS (FR0013254851 – ALVAL / eligible PEA/SMES), a company specializing in the development of nutritional solutions, innovative, dedicated to the prevention of cardio-metabolic and to cover patients ‘ nutritional, announces today that it will present a synthesis of the results of its clinical study Phase I/II [1] on the active principle of Valedia®, Totum-63, at 77èmes scientific sessions of the American Diabetes Association (ADA) which will be held from 9 to 13 June 2017 at San Diego (California, USA).
The summary of the results of the clinical study Phase I/II validating the safety and first evidence of efficacy of the active principle will be presented by Sébastien Peltier, CEO of VALBIOTIS, in the form of a poster entitled “Phase 1 Clinical Trial to Evaluate a Botanical Complex for Managing Prediabetes” (1244-P), Sunday 11 June 2017 12: 00 to 13: 00 (Hall B).
Valedia®, whose active principle is Totum-63, is a patented combination of innovative plant extracts for the prevention of type 2 diabetes. VALBIOTIS is currently obtaining a health claim for convention concerning the reduction of a risk factor for type 2 diabetes that will position Valedia® as the first product in the world with a health claim for pre-diabetes the number of which reached almost 130 million for the only european and us markets. The support of pre-diabetes, a state at risk of type 2 diabetes, would have the effect of delaying the disease, or even to return to a normal physiological state.
About scientific sessions of the American Diabetes Association
Organized each year, the scientific sessions of the ADA are imposed as the worldwide event of reference of diabetes. It attracts every year more than 13 000 people : researchers, health professionals and industry to present innovative research and the latest advances in the treatment and follow-up of diabetes [2].
ABOUT VALBIOTIS
VALBIOTIS is a company specialized in the development of nutritional solutions, innovative, dedicated to the prevention of cardio-metabolic and to cover patients ‘ nutritional. Its products are intended for manufacturers of the agri-food industry, and the pharmaceutical industry. VALBIOTIS intervenes in particular for the prevention of type 2 diabetes, NASH (nonalcoholic steatohepatitis), obesity and cardio-vascular diseases.
Created in early 2014 in La Rochelle, the Company has formed numerous partnerships with academic centres of excellence in France and abroad, including the University of la Rochelle, CNRS, and the University of Clermont Auvergne is located in Clermont-Ferrand, where the Company has opened a secondary institution. These agreements allow him to benefit from his creation of the strong effect of leverage, including through experts and technical partners engaged on its projects. A member of the network “BPI Excellence” and benefiting from the label on the BPI ” Innovative Company “, VALBIOTIS also has the status of “Young Innovative Company” and has obtained important financial support of the European Union for its research programs through the obtaining of European Funds for Economic Development Regional (FEDER).
All the information on VALBIOTIS :
http://valbiotis.com/
Download the free guide
Boost your gains
